This post was originally published on this site
MRNA stock has lost 42.8% in price over the past month to close Friday’s trading session at $257.06. MRNA has received several orders for its COVID-19 vaccine. For example, on December 1, it announced a revised supply agreement with the U.K. government for up to 60 million doses. However, its COVID-19 vaccine is the company’s only commercial product, while its other products are still in in clinical trial stages.
MRNA’s stock declined nearly 10% in price on December 1, after the company lost a patent dispute. Also, MRNA’s CEO recently sold 19,000 shares. So, MRNA’s near-term prospects look uncertain.
